Secretome Therapeutics

DALLAS, TX · Founded 2018 · Biotech · Private

Neonatal cell-derived therapeutic products manufactured from engineered cell sources

Claim this profile

Follows are private to you and power your alerts

Updated · secretometherapeutics.com

Sector
Biotech
Headquarters
DALLAS, TX
Founded
2018
Latest Form D
$6.9M, Feb 2023
Total capital
$6.9M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$6.9M
1 Form D · last Feb 2023
45 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
4 pending

Capital timeline

2023FEDERAL ↑EQUITY ↓Cumulative $6.9M1st Form D$6.9M
2023FEDERAL ↑EQUITY ↓Cumulative $6.9M1st Form D$6.9M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$6.9M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • ANGELA SHENDirectorNamed in SEC Form D filings
  • HENRIK RASMUSSENDirectorNamed in SEC Form D filings
  • SUNJAY KAUSHALDirectorNamed in SEC Form D filings
  • VINEET JINDALExecutive Officer, DirectorNamed in SEC Form D filings
  • WILLIAM NILANDDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 4
  • PendingImmortalized Cardiac Stem Cells For Cardiac RepairUSPTOApplication 17776839
  • PendingMethods Of Treating Amyotrophic Lateral SclerosisUSPTOApplication PCTUS2025052405
  • PendingMethods Of Treating Amyotrophic Lateral SclerosisUSPTOApplication 63769522
Show all 4 patent records
  • Immortalized Cardiac Stem Cells For Cardiac RepairDec 8, 2022 · Application 17776839Pending
  • Methods Of Treating Amyotrophic Lateral SclerosisApplication PCTUS2025052405Pending
  • Methods Of Treating Amyotrophic Lateral SclerosisApplication 63769522Pending
  • Methods Of Treating Amyotrophic Lateral SclerosisApplication 63712683Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .